Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that lower GPX4 mRNA levels in polymorphonuclear neutrophils of systemic lupus erythematosus patients were negatively associated with disease activity and serological markers, suggesting a diagnostic value for GPX4 mRNA.

In this study, chronic telogen effluvium was identified as the most common cause of alopecia in patients with systemic lupus erythematosus, with trichoscopy proving effective in diagnosing different alopecia patterns.

In this study involving 30 Kazakh women with systemic lupus erythematosus, the researchers found a strong correlation between disease activity (SELENA-SLEDAI scores) and organ damage (SLICC/ACR scores), which depended on disease duration and reliably reflected cumulative disease activity.

This study concluded that laser hair removal using Alexandrite laser emitting red and infrared light appears safe and does not significantly affect the disease activity of Systemic lupus erythematosus.

This study found that trichoscopic examination is useful for diagnosing and monitoring systemic lupus erythematosus, with severe diffuse non-scarring alopecia indicating active disease.

The study reported a 7.80% prevalence of scarring alopecia in Chinese SLE patients and identified several risk factors, including mucocutaneous lesions and high disease activity, while renal and cardio-respiratory involvements were negatively associated with it.

In this multicenter study, belimumab effectively reduced disease activity in systemic lupus erythematosus patients with joint and skin manifestations, showing significant improvement in acute and subacute skin types earlier than in chronic types, while no significant benefit was observed for nonspecific skin manifestations.

This review discusses the various common, rare, and unusual skin manifestations of lupus erythematosus and highlights the importance of accurate diagnosis, but it reports no new clinical results.

This review summarizes various indices used to assess disease activity and damage in systemic lupus erythematosus, highlighting challenges in universal consensus and their practical applications in research and clinical settings.

This study observed that non-scarring diffuse hair loss was common in systemic lupus erythematosus patients, but did not find a significant relationship with the SLE Disease Activity Index.

This case report describes a 15-year-old female whose initial systemic lupus erythematosus manifestations were fever and rash appearing separately, illustrating diagnostic challenges between SLE and infection.

In this study, cutaneous features like hair loss, malar rash, and photosensitivity were identified as key indicators of disease activity in systemic lupus erythematosus.

This study observed that in a real-world clinical setting in Greece, belimumab effectively controlled disease activity in lupus patients and allowed for a reduction in glucocorticoid dosage, with more pronounced benefits seen in patients who were serologically active at the start of treatment.

This study found that anifrolumab effectively reduced disease activity and allowed for corticosteroid tapering in patients with systemic lupus erythematosus at Kanazawa University Hospital.

Certain proteins involved in DNA modification may affect the genetic changes in systemic lupus erythematosus and could indicate the disease's activity.

This study identified hemoglobin level as the strongest biological predictor of fatigue in systemic lupus erythematosus patients, highlighting its association with disease activity and systemic inflammation.

This study reports that a lower 2D:4D finger length ratio is significantly associated with higher disease activity and reduced spinal mobility in females with ankylosing spondylitis, but not in males.

This article discusses the classification and significance of cutaneous manifestations in systemic lupus erythematosus, emphasizing the importance of recognizing these skin features for disease management, but reports no new clinical results.

This study found that belimumab helped achieve low disease activity in over 40% of systemic lupus erythematosus patients in real-life settings, alongside reduced corticosteroid use and fewer flares.

This chapter reviews the development of skin-specific outcome instruments for autoimmune diseases like cutaneous lupus erythematosus and dermatomyositis, highlighting a need for a broader community-involved process across other diseases but reports no new results.

This study provides insights into systemic lupus erythematosus patients' experiences with Anifrolumab, highlighting improvements in symptoms and health-related quality of life, despite ongoing daily life impacts.

This study found that simultaneous presence of specific and nonspecific skin lesions, or having three or more types of skin lesions, was associated with increased systemic activity of systemic lupus erythematosus.

This study reported a 2.6% prevalence of myositis in patients with systemic lupus erythematosus, with alopecia, leukopenia, and active disease significantly associated with its development.

This review discusses approaches to diagnosing and managing cutaneous manifestations of lupus erythematosus and reports no new clinical results.

This study found that fibromyalgia prevalence is slightly higher in patients with systemic lupus erythematosus compared to those with arthritis, but fibromyalgia-ness does not bias the SLE Activity Questionnaire.

In this study, hydroxychloroquine use was associated with a delayed onset of integument damage in SLE patients, while higher disease activity over time predicted quicker damage development.

This study found that the Cutaneous Lupus Disease Area and Severity Index (CLASI) is correlated with both physician-assessed and patient-reported outcomes in cutaneous lupus erythematosus, particularly highlighting concerns about body image in visible areas.

This article reviews the classification and treatment of cutaneous manifestations in systemic lupus erythematosus, highlighting the importance of monitoring for disease progression and reports no new clinical results.

This study observed that certain skin symptoms in SLE, such as malar rash and photosensitivity, are linked to systemic involvement, indicating their potential role as markers for disease activity.

This report presents the early development of the Lupus Foundation of America's LFA-REAL™ patient-reported instrument, designed to enhance evaluation of lupus disease activity by combining patient and physician assessments.